|
1
|
Poole JC, Andrews LG and Tollefsbol TO:
Activity, function, and gene regulation of the catalytic subunit of
telomerase (hTERT). Gene. 269:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakamura TM, Morin GB, Chapman KB, et al:
Telomerase catalytic subunit homologs from fission yeast and human.
Science. 277:955–959. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenberg RA, O’Hagan RC, Deng H, Xiao Q,
Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB and DePinho RA:
Telomerase reverse transcriptase gene is a direct target of c-Myc
but is not functionally equivalent in cellular transformation.
Oncogene. 18:1219–1226. 1999. View Article : Google Scholar
|
|
4
|
Kanaya T, Kyo S, Hamada K, Takakura M,
Kitagawa Y, Harada H and Inoue M: Adenoviral expression of p53
represses telomerase activity through down-regulation of human
telomerase reverse transcriptase transcription. Clin Cancer Res.
6:1239–1247. 2000.
|
|
5
|
Abdul-Ghani R, Ohana P, Matouk I, Ayesh S,
Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA,
et al: Use of transcriptional regulatory sequences of telomerase
(hTER and hTERT) for selective killing of cancer cells. Mol Ther.
2:539–544. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koga S, Hirohata S, Kondo Y, Komata T,
Takakura M, Inoue M, Kyo S and Kondo S: A novel telomerase-specific
gene therapy: gene transfer of caspase-8 utilizing the human
telomerase catalytic subunit gene promoter. Hum Gene Ther.
11:1397–1406. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koga S, Hirohata S, Kondo Y, Komata T,
Takakura M, Inoue M, Kyo S and Kondo S: FADD gene therapy using the
human telomerase catalytic subunit (hTERT) gene promoter to
restrict induction of apoptosis to tumors in vitro and in vivo.
Anticancer Res. 21:1937–1943. 2001.PubMed/NCBI
|
|
8
|
Komata T, Koga S, Hirohata S, Takakura M,
Germano IM, Inoue M, Kyo S, Kondo S and Kondo Y: A novel treatment
of human malignant gliomas in vitro and in vivo: FADD gene transfer
under the control of the human telomerase reverse transcriptase
gene promoter. Int J Oncol. 19:1015–1020. 2001.PubMed/NCBI
|
|
9
|
Komata T, Kondo Y, Kanzawa T, Hirohata S,
Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura
M, et al: Treatment of malignant glioma cells with the transfer of
constitutively active caspase-6 using the human telomerase
catalytic subunit (human telomerase reverse transcriptase) gene
promoter. Cancer Res. 61:5796–5802. 2001.
|
|
10
|
Komata T, Kondo Y, Kanzawa T, Ito H,
Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP, et
al: Caspase-8 gene therapy using the human telomerase reverse
transcriptase promoter for malignant glioma cells. Hum Gene Ther.
13:1015–1025. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gu J, Kagawa S, Takakura M, Kyo S, Inoue
M, Roth JA and Fang B: Tumor-specific transgene expression from the
human telomerase reverse transcriptase promoter enables targeting
of the therapeutic effects of the Bax gene to cancers. Cancer Res.
60:5359–5364. 2000.
|
|
12
|
Majumdar AS, Hughes DE, Lichtsteiner SP,
Wang Z, Lebkowski JS and Vasserot AP: The telomerase reverse
transcriptase promoter drives efficacious tumor suicide gene
therapy while preventing hepatotoxicity encountered with
constitutive promoters. Gene Ther. 8:568–578. 2001. View Article : Google Scholar
|
|
13
|
Gu J, Andreeff M, Roth JA and Fang B:
hTERT promoter induces tumor-specific Bax gene expression and cell
killing in syngenic mouse tumor model and prevents systemic
toxicity. Gene Ther. 9:30–37. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Q, Wei YQ, Wen YJ, et al: Induction of
apoptosis and tumor regression by vesicular stomatitis virus in the
presence of gemcitabine in lung cancer. Int J Cancer. 112:143–149.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaddy DF and Lyles DS: Oncolytic vesicular
stomatitis virus induces apoptosis via signaling through PKR, Fas,
and Daxx. J Virol. 81:2792–2804. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balachandran S and Barber GN: Vesicular
stomatitis virus (VSV) therapy of tumors. IUBMB Life. 50:135–138.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Balachandran S, Porosnicu M and Barber GN:
Oncolytic activity of vesicular stomatitis virus is effective
against tumors exhibiting aberrant p53, Ras, or myc function and
involves the induction of apoptosis. J Virol. 75:3474–3479. 2001.
View Article : Google Scholar
|
|
18
|
Stojdl DF, Lichty BD, tenOever BR, et al:
VSV strains with defects in their ability to shutdown innate
immunity are potent systemic anti-cancer agents. Cancer Cell.
4:263–275. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shinozaki K, Ebert O, Kournioti C, Tai YS
and Woo SL: Oncolysis of multifocal hepatocellular carcinoma in the
rat liver by hepatic artery infusion of vesicular stomatitis virus.
Mol Ther. 9:368–376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahmed M, Cramer SD and Lyles DS:
Sensitivity of prostate tumors to wild type and M protein mutant
vesicular stomatitis viruses. Virology. 330:34–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kopecky SA and Lyles DS: The cell-rounding
activity of the vesicular stomatitis virus matrix protein is due to
the induction of cell death. J Virol. 77:5524–5528. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kopecky SA and Lyles DS: Contrasting
effects of matrix protein on apoptosis in HeLa and BHK cells
infected with vesicular stomatitis virus are due to inhibition of
host gene expression. J Virol. 77:4658–4669. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gaddy DF and Lyles DS: Vesicular
stomatitis viruses expressing wild-type or mutant M proteins
activate apoptosis through distinct pathways. J Virol.
79:4170–4179. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmed M, McKenzie MO, Puckett S, Hojnacki
M, Poliquin L and Lyles DS: Ability of the matrix protein of
vesicular stomatitis virus to suppress beta interferon gene
expression is genetically correlated with the inhibition of host
RNA and protein synthesis. J Virol. 77:4646–4657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong Q, Wen YJ, Yang HS, et al: Efficient
inhibition of cisplatin-resistant human ovarian cancer growth and
prolonged survival by gene transferred vesicular stomatitis virus
matrix protein in nude mice. Ann Oncol. 19:1584–1591. 2008.
View Article : Google Scholar
|
|
26
|
Zhao JM, Wen YJ, Li Q, et al: A promising
cancer gene therapy agent based on the matrix protein of vesicular
stomatitis virus. FASEB J. 22:4272–4280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du XB, Lang JY, Xu JR, et al: Vesicular
stomatitis virus matrix protein gene enhances the antitumor effects
of radiation via induction of apoptosis. Apoptosis. 13:1205–1214.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi W, Tang Q, Chen X, et al: Antitumor
and antimetastatic activities of vesicular stomatitis virus matrix
protein in a murine model of breast cancer. J Mol Med. 87:493–506.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo S, Chen P, Luo ZC, Zhang P, et al:
Combination of vesicular stomatitis virus matrix protein gene
therapy with low-dose cisplatin improves therapeutic efficacy
against murine melonoma. Cancer Sci. 101:1219–1225. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Horikawa I, Cable PL, Afshari C and
Barrett JC: Cloning and characterization of the promoter region of
human telomerase reverse transcriptase gene. Cancer Res.
59:826–830. 1999.PubMed/NCBI
|
|
31
|
Painter RG, Lanson NA Jr, Jin Z, et al:
Conditional expression of a suicide gene by the telomere reverse
transcriptase promoter for potential post-therapeutic deletion of
tumorigenesis. Cancer Sci. 96:607–613. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shieh GS, Shiau AL, Yo YT, et al: Low-dose
etoposide enhances telomerase-dependent adenovirus-mediated
cytosine deaminase gene therapy through augmentation of adenoviral
infection and transgene expression in a syngeneic bladder tumor
model. Cancer Res. 66:9957–9966. 2006. View Article : Google Scholar
|
|
33
|
Wirth T, Zender L, Schulte B, Mundt B, et
al: A telomerase-dependent conditionally replicating adenovirus for
selective treatment of cancer. Cancer Res. 63:3181–3188.
2003.PubMed/NCBI
|
